Differences
This shows you the differences between two versions of the page.
| Next revisionBoth sides next revision | |||
| content:α-aasa [2020/02/16 17:25] – created icna | content:α-aasa [2020/02/16 17:26] – [Interpretation] icna | ||
|---|---|---|---|
| Line 7: | Line 7: | ||
| * α-Amino adipic semialdehyde (α-AASA) accumulates in body fluids from patients with pyridoxine-dependent epilepsy because of mutations in antiquitin (ALDH7A1) and serves as the biomarker for this condition. | * α-Amino adipic semialdehyde (α-AASA) accumulates in body fluids from patients with pyridoxine-dependent epilepsy because of mutations in antiquitin (ALDH7A1) and serves as the biomarker for this condition. | ||
| - | * urinary excretion of α-AASA is also increased in [[molybdenum cofactor]] and [[sulfite oxidase]] deficiencies[(: | + | * urinary excretion of α-AASA is also increased in [[molybdenum cofactor]] and [[sulfite oxidase]] deficiencies[(: |
| ==== References ==== | ==== References ==== | ||
| ~~REFNOTES~~ | ~~REFNOTES~~ | ||